{"id":45768,"date":"2022-07-04T12:02:17","date_gmt":"2022-07-04T10:02:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/21-cfr-part-11-fda-guidance-for-electronic-records-and-electronic-signatures-webinar-researchandmarkets-com\/"},"modified":"2022-07-04T12:02:17","modified_gmt":"2022-07-04T10:02:17","slug":"21-cfr-part-11-fda-guidance-for-electronic-records-and-electronic-signatures-webinar-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/21-cfr-part-11-fda-guidance-for-electronic-records-and-electronic-signatures-webinar-researchandmarkets-com\/","title":{"rendered":"21 CFR Part 11: FDA Guidance for Electronic Records and Electronic Signatures Webinar – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “21 CFR Part 11, FDA’s Guidance for Electronic Records and Electronic Signatures”<\/a> webinar has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis webinar is intended for those involved in planning, execution and support of computer system validation activities, working in the FDA-regulated industries, including pharmaceutical, medical device, biologics, tobacco and tobacco-related products (e-liquids, e-cigarettes, pouch tobacco, cigars, etc.).\n<\/p>\n

\nFunctions that are applicable include research and development, manufacturing, Quality Control, distribution, clinical testing and management, sample labeling, adverse events management and post-marketing surveillance.\n<\/p>\n

\nThis webinar will help you understand in detail the application of FDA’s 21 CFR Part 11 guidance on electronic records\/electronic signatures (ER\/ES) for computer systems subject to FDA regulations. This is critical in order to develop the appropriate validation strategy and achieve the thoroughness required to prove that a system does what it purports to do.\n<\/p>\n

\nIt also ensures that a system is maintained in a validated state throughout its entire life cycle, from conception through retirement. ER\/ES capability can vary, and the approach should be based on the specific case and the risk of failing to meet the guidance associated with it.\n<\/p>\n

\nFDA’s 21 CFR Part 11 was enacted in the late 1990s and implementation success across the pharmaceutical and other regulated industries has been mixed. There are very specific limitations that arise when using ER\/ES capability, such as the elimination of print capability to prevent users from making decisions based on a paper record as opposed to the electronic record.\n<\/p>\n

\nIt also requires very specific identification of users that ensures the person signing the record is the same person whose credentials are being entered and verified by the system. Rules for changing passwords must be rigorously adhered to and the passwords must be kept secure.\n<\/p>\n

\nIt is also critical that the system specify the exact meaning of the signature. It may be that the person conducted the work, recorded the result, reviewed the result, or approved the result. A person may simply be attesting to the fact that they reviewed the work and the signatures, and there was appropriate segregation of duties (i.e., the person recording the result is not the same as either the person reviewing or the person giving final approval).\n<\/p>\n

\nA company must have specific policies and procedures in place that explicitly state responsibilities and provide guidance for implementing and using ER\/ES capability. These must clarify the 21 CFR Part 11 regulation and provide insight as to the way the company interprets their responsibility for meeting it. As FDA continues to evolve and change due to the many factors that influence the regulatory environment, companies must be able to adapt.\n<\/p>\n

\nNew technologies will continue to emerge that will change the way companies do business. While many of these are intended to streamline operations, reducing time and resources, some unintentionally result in added layers of oversight that encumber a computer system validation program and require more time and resources, making the technology unattractive from a cost-benefit perspective.\n<\/p>\n

\nWho will benefit from this webinar include:<\/strong>\n<\/p>\n